Hu Huang
Research Subjects
Hu Huang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Huailong Chang
Global R&D Center Shanghai Chicmax Cosmetic Co. Ltd., China
1 shared publication - Jiahua Cui
School of Pharmacy, Gannan Medical University, Ganzhou 341000, China
1 shared publication - Jinping Jia
School of Environmental Science and Engineering, Shanghai Jiao Tong University, 800 Dong Chuan Road, Shanghai 200240, P. R. China
1 shared publication - Kan Tao
Global R&D Center Shanghai Chicmax Cosmetic Co. Ltd., China
1 shared publication - Shah Nawaz Khan
School of Chemistry and Chemical Engineering Shanghai Jiaotong University Shanghai China
1 shared publication
Latest Publications
- Open Access
- 15 October 2024
- Published by MDPI AG in Preprints.org
Discovery of A Novel Cyclopeptide as Tyrosinase Inhibitor for Skin Lightening
Melanin content significantly influences the skin-lightening effects of active ingredients, with inhibition of melanin synthesis contributing to skin-lightening effects. This study evaluates the effects of novel cyclopeptide CHP-9 as a safe and potent human tyrosinase inhibitor. CHP-9 showed a significant inhibition rate of approximately 28.57% at 1% concentration. The melanin formation assay, upon exposure to CHP-9 alone, resulted in a reduction of cellular melanin content from 30.90±1.13 μg/mL to 23.51±1.14 μg/mL. Additionally, in silico molecular docking experiments were conducted to verify the tyrosinase inhibitory activity of the cyclopeptide CHP-9 on tyrosinase and it was observed that hydrogen bonding is pivotal in the binding affinity of CHP-9 with the target enzyme in docking. These results suggest that the cyclopeptide CHP-9 may serve as a valuable bioactive compound for skin-lightening agents in cosmetics applications, specifically in reducing melanin production.
- 15 October 2024
- Published by MDPI AG in Preprints.org
Open AccessDiscovery of A Novel Cyclopeptide as Tyrosinase Inhibitor for Skin Lightening
Melanin content significantly influences the skin-lightening effects of active ingredients, with inhibition of melanin synthesis contributing to skin-lightening effects. This study evaluates the effects of novel cyclopeptide CHP-9 as a safe and potent human tyrosinase inhibitor. CHP-9 showed a significant inhibition rate of approximately 28.57% at 1% concentration. The melanin formation assay, upon exposure to CHP-9 alone, resulted in a reduction of cellular melanin content from 30.90±1.13 μg/mL to 23.51±1.14 μg/mL. Additionally, in silico molecular docking experiments were conducted to verify the tyrosinase inhibitory activity of the cyclopeptide CHP-9 on tyrosinase and it was observed that hydrogen bonding is pivotal in the binding affinity of CHP-9 with the target enzyme in docking. These results suggest that the cyclopeptide CHP-9 may serve as a valuable bioactive compound for skin-lightening agents in cosmetics applications, specifically in reducing melanin production.